The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 29, No. 11, pp. 1115-1117.
© 1995 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canovas Martinez, A
Right arrow Articles by Delgado Cordon, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canovas Martinez, A
Right arrow Articles by Delgado Cordon, F


Research Articles

Vigabatrin-associated reversible acute psychosis in a child

A Canovas Martinez, JP Ordovas Baines, M Beltran Marques, A Escriva Aparisi, and F Delgado Cordon

OBJECTIVE: To describe a child with vigabatrin-associated reversible acute psychosis and review the literature reports on this adverse effect. CASE SUMMARY: A 7-year-old boy with intractable epilepsy developed acute psychosis 3 days after initiating a rapid vigabatrin dosage escalation. All symptoms resolved within 48 hours after vigabatrin therapy was withdrawn. Two months later, reinitiation of vigabatrin therapy using a slower dosage escalation was well-tolerated by the patient, and he currently is being treated with vigabatrin successfully. DISCUSSION: Although vigabatrin-associated psychosis is rare, a few cases have been reported in predisposed adult patients, especially in the early stages of treatment. The mechanism of this reaction remains unclear and its incidence is unknown. To our knowledge, there has been no previous report of this adverse effect in children. CONCLUSIONS: Caution must be taken in children with predisposing factors at the beginning of vigabatrin therapy.





homecopy help contact us subscription past issues search current issue
Copyright © 1995 by Harvey Whitney Books Company.